CTLA4 and hepatocellular carcinoma: The objective response rate (ORR) of patients with CTLA-4 mAb monotherapy was low (43), so the combination of CTLA-4 mAb with other therapeutic methods may be the future direction of CTLA-4 antibody development in HCC (46, 47).